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Edited by Jesus AvilaAbstract Ropinirole, a D2/D3 receptor agonist has been
reported to have neuroprotective eﬀects. We showed that ropin-
irole can prevent rotenone-induced apoptosis in dopaminergic
cell line SH-SY5Y through D3 receptor. We found that ropini-
role can block the rotenone-induced phosphorylation of JNK,
P38 and p-c-Jun, but promote the phosphorylation of ERK1/2.
Furthermore, we demonstrated that ropinirole can reduce the
rotenone-induced cleavages of caspase 9, caspase 3 and PARP
and elevate the expression of anti-apoptotic proteins of p-Akt
and bcl-2. These results provide a basis for neuroprotection by
this drug for the treatment of Parkinson disease.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Parkinson disease (PD) is a progressive neurodegenerative
disorder characterized by continuous neuronal loss in the sub-
stantia nigra (SN) [1,2]. Although the etiology of PD in most
cases is not clear, it is likely to result from the combination
of environmental and genetic factors leading to mitochondrial
dysfunction, oxidative stress, and eventually nigral dopaminer-
gic neuron degeneration [3].
Rotenone, an inhibitor to mitochondrial complex I, has been
shown to produce some pathological features of PD in rat
model [4–6]. It has been reported that rotenone can induce
dopaminergic neuron apoptosis through activation ofAbbreviations: BDNF, brain derived neurotrophic factor; DAT,
dopamine transporter; ERK1/2, extracellular-signal regulated kinase
1/2; GDNF, glial-derived neurotrophic factor; JNK, c-Jun NH2-
terminal kinase; MAPK, mitogen-activated protein kinase; PARP,
poly [Aop] ribose polymerase; PD, Parkinson disease; SN, substantia
nigra
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pase-dependent pathway [7,8]. MAPK subfamilies including
extracellular-signal regulated kinase 1/2 (ERK1/2), c-Jun
NH2-terminal kinase (JNK), and P38 MAPK play diverse
roles in the neuronal diﬀerentiation, survival and death
[9,10]. ERK1/2 is preferentially activated by growth factors,
which participates in neuronal growth and diﬀerentiation
[11–13]; while JNK and P38 can be activated by cell stress-
inducing signals [9,10]. Sustained activation of JNK and P38
is associated with apoptosis in neurons [9,10]. Cleaved caspase
9, which is activated by mitochondrial impairment, represents
an internal apoptotic pathway [14,15]. Caspase 3 and poly
[Aop] ribose polymerase (PARP) are main downstream signals
of caspase 9 [16]. Inhibition of these apoptotic signals may pro-
vide neuroprotection and beneﬁt for neuronal survival.
Dopamine receptor agonists are widely used in the treatment
of PD as monotherapy or as adjunctive drugs to relieve levo-
dopa-related motor ﬂuctuations. Furthermore, these agents
may have multiple neuroprotective eﬀects [17–20]. Real-PET
study to evaluate the function of dopamine transporter
(DAT) showed that D2/D3 agonist ropinirole treatment may
delay disease progression in PD patients [21]. However, consid-
erable uncertainty now exists about the validity of this method
in assessing neuroprotection. Our previous in vitro study
showed that ropinirole can promote the diﬀerentiation and sur-
vival of dopaminergic neurons, and can upregulate the expres-
sion and secretion of glial-derived neurotrophic factor (GDNF)
and brain derived neurotrophic factor (BDNF) [22].
Considering the potential eﬀects of ropinirole in neuropro-
tection, we hypothesize that ropinirole may have an anti-apop-
totic eﬀect through interfering with MAP kinase pathway and
caspase-dependent pathway. We have tested this hypothesis in
SH-SY5Y, a human dopaminergic cell line that is often used
for the study of the mechanisms of neurodegeneration relevant
to PD.2. Materials and methods
2.1. Cell cultures
SH-SY5Y cells were routinely grown in Dulbeccos modiﬁed Eagles
medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (GIBCO, Gaithersburg, USA), 100 lg/mL pecicillin,
100 lg/mL streptomycin and cultured at 37 C under humidiﬁed 5%blished by Elsevier B.V. All rights reserved.
Fig. 1. Ropinirole protects SH-SY5Y cells and primary ventral mesencephalic dopaminergic neurons against rotenone-induced apoptosis. (A,a–f: SH-
SY5Y cells.) (A,a) Rotenone at 10 lMfor 12 h. (A,b) Pretreatment with ropinirole at 50 lMfor 2 h before 10 lMrotenone addition. (A,c) Rotenone at
20 lMfor 12 h. (A,d) Pretreatment with ropinirole at 50 lMfor 2 h before 20 lMrotenone addition. (A,e) Ropinirole at 50 lMfor 12 h. (A, f) Control.
(A,g–l: primary VM cultures; g–i: TH staining; j–l: double staining with TH and Hoechst 33258.) (A,g) Rotenone 10 nM for 12 h. (A,h) Ropinirole at
10 lM2 hbefore rotenone 10 nMaddition. (A, i)Normal control. (A, j)Rotenone at 10 nMfor 12 h. (A,k)Rotenone at 30 nMfor 12 h. (A, l)Ropinirole
at 10 lM2 hbefore 10 nMrotenone addition. (B)Anti rotenone-induced apoptosis by ropinirole at 10 lM, 20 lM, 50 lMand 100 lMpretreatment 2 h
before 10 lM or 20 lM rotenone addition for 12 h in SH-SY.5Y cells. *P < 0.05, **P < 0.01. (C) Ropinirole-mediated anti-apoptosis could be
suppressed by sulpiride and nafadotride in SH-SY5Y cells. Rotenone treatment at 10 lM or 20 lM for 12 h; some cultures were pretreated with
ropinirole at 50 lM for 2 h, or sulpiride or nafadotride treatment at 50 lM for 2 h before ropinirole and then rotenone addition. **P < 0.01 (Rot 10 or
20 lMvs. Rop 50 lMpre). #P < 0.05, ##P < 0.01 (D2 ant or D3 ant or D2 + D3 ant vs. Rot 10 or 20 lM). &P < 0.05, &&P < 0.01 (D2 ant or D3 ant or
D2 + D3 ant vs. Rop 50 lM). Rot: Rotenone, Rop: Ropinirole (each experimental was repeated three times).
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Fig. 2. Ropinirole inhibits the activation of JNK and P38 pathway induced by rotenone. Detection of p-P38 (A,B) and p-JNK (C,D). (A,C): a,
rotenone at 10 lM for 30 min; b, ropinirole at 50 lM pretreatment for 30 min before 10 lM rotenone addition for 30 min; c, ropinirole at 50 lM for
30 min; d, control. (B,D): a, rotenone at 10 lM for 60 min; b, ropinirole at 50 lM pretreatment for 30 min before 10 lM rotenone addition for
60 min; c, ropinirole at 50 lM for 60 min; d, control. (E) Detection of p-c-Jun: a, rotenone at 10 lM for 2 h; b, ropinirole at 50 lM pretreatment for
30 min before 10 lM rotenone addition for 2 h; c, ropinirole at 50 lM for 2 h; d, control. *P < 0.05, **P < 0.01 (each experimental was repeated three
times).
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media containing 10 lM retinoic acid for 3 days before rotenone and
ropinirole addition.
Primary ventral mesencephalic cells (VM) were isolated and cultured
according to the method described previously [22]. For collecting
conditioned medium, the cell suspension was plated at a ﬁnal density
of 3 · 105 viable cells/cm2 in a 60-mm culture dish (Nunc) precoated
with poly-L-lysine and laminin. After 24 h, ropinirole or other agents
were added into the medium when serum-containing medium was
changed to serum-free medium supplemented with 2% B27.
2.2. Drugs and treatments
Rotenone (Sigma, St. Louis, MO, USA) was made freshly in di-
methyl sulfoxide prior to each experiment. Ropinirole (GlaxoSmithK-
line, USA), D2 receptor antagonist sulpiride (Sigma) and D3
antagonist nafadotride (Sigma) were made freshly in water. Ropinirole
was added 2 h before rotenone addition in the cultures to evaluate the
anti-apoptotic eﬀect. To examine whether the anti-apoptotic eﬀects ofFig. 3. Ropinirole induces expression of p-ERK. Ropinirole increased the lev
Rotenone treatment did not change ropinirole induced p-ERK expression (C
for 30 min before 10 lM rotenone addition for 30 min; c, ropinirole at 50 lM
repeated three times).ropinirole was mediated via D2 or D3 receptors, sulpiride and nafadot-
ride were added into cultures 2 h before ropinirole addition.
2.3. Apoptosis assay
For microscopic nuclear DNA analysis, SH-SY5Y cells were stained
with Hoechst 33258 (Molecular Probe, Eugene, USA). The cells with
condensed or fragmented nuclei as determined by ﬂuorescent micro-
scope were considered to be apoptotic. Uniformly stained nuclei were
scored as healthy, viable neurons. Eight ﬁelds were counted in each
group in a blind fashion. The number of apoptotic cells was expressed
as a percentage of the total cells we observed. Each experimental was
repeated three times.
2.4. Immunohistochemistry
Primary VM cultures were ﬁxed in 4% paraformaldehyde. The
monoclonal anti-tyrosine hydroxylase (TH) antibody at 1:3000 (Sig-
ma) and second antibody with Cy3 conjugation at 1:1000 were used.el of p-ERK at the dose-dependent (A) and time-dependent manner (B).
). a, Rotenone at 10 lM for 30 min; b, ropinirole at 50 lM pretreated
for 30 min; d: control. *P < 0.05, **P < 0.01 (each experimental was
Fig. 4. Ropinirole inhibits the caspase-dependent apoptotic pathway. Ropinirole inhibited the activation of cleaved caspase 9 (A), cleaved caspase 3
(B) and cleaved PARP (C). a, Rotenone at 10 lM for 12 h; b, ropinirole at 50 lM pretreated for 2 h before 10 lM rotenone addition for 12 h; c,
ropinirole at 50 lM for 12 h; d, control. *P < 0.05, *P < 0.01 (each experimental was repeated three times).
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cence microscopy (Olympus AX80 ﬂuorescence microscope).
2.5. Immunoblot analysis
After speciﬁc treatment, SH-SY5Y cells were lysed in RIPA lysis buf-
fer and loaded onto 12% SDS–polyacrylamide gel for electrophoresis.
The proteins were transferred onto polyvinylidene diﬂuoride (PVDF)
membrane and incubated with primary antibody phosphor-ERK1/2
(1:1000; Cell signaling, USA), phosphor-JNK (1:1000; Thr 183 and
Tyr 185, Cell signaling), phosphor-P38 (1:1000; Thr 180 and Tyr 182,
Cell signaling), phosphor-c-Jun (1:1000; Ser 73, Cell signaling), PARP
and cleavage (1:1000; Cell signaling), caspase-9 and cleavage (1:1000;
Cell signaling), cleaved caspase-3 (1:1000; Cell signaling). p-Akt (473)
(1:1000; Cell signaling), Bcl-2 (1:1000; Santa Cruz Biotechnology,
USA). After wash, the blot was incubated with peroxidase-conjugated
secondary goat anti-rabbit IgG (Pierce, IL, USA), or goat anti-mouse
IgG (Pierce Biotechnology, USA), and developed with Super Signal
West Dura Extended Duration Substrate (Pierce). The results of Wes-
tern blots were quantiﬁed with an image analyzer (Bio-Rad, Quantity
One-4.2.0, USA). Each experimental was repeated three times.
2.6. Statistical analysis
Data were represented as mean ± S.E. and diﬀerences between
groups were tested for signiﬁcance using one-way or two-way analysisof variance (ANOVA) followed by Bonferonnis post hoc analysis. A P
value of less than 0.05 was denoted statistical signiﬁcance.3. Results
3.1. Ropinirole suppresses rotenone induced apoptosis
Treatment with 10 lM or 20 lM rotenone for 12 h resulted
in 32% or 38% apoptotic cell death in SH-SY5Y cells. Pretreat-
ment with ropinirole at 50 lM for 2 h prior to rotenone (10–
20 lM) explore signiﬁcantly inhibited SH-SY5Y apoptosis by
68–69% (Fig. 1A and B). To observe the dose-dependent
anti-apoptotic eﬀect, SH-SY5Y cells were pretreated with
diﬀerent doses of ropinirole (10 lM, 20 lM, 50 lM and
100 lM) for 2 h followed by rotenone. It was found the rote-
none-induced apoptosis was inhibited by 58–67% with ropini-
role when the cells were treated with 10 lM of rotenone or by
29–68% with ropinirole when the cells were treated with 20 lM
of rotenone. To determine whether DA receptors contribute to
the neuroprotection of ropinirole, we pretreated the cultures
Fig. 5. Ropinirole promotes the expression of p-Akt and Bcl-2. Ropinirole promoted the expression of p-Akt and Bcl-2 at dose-dependent manner
and time-dependent manner (A,B). Rotenone treatment down-regulated the expression of p-Akt and Bcl-2, which could be suppressed by
pretreatment with ropinirole at 50 lM for 2 h (C) (each experimental was repeated three times).
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ide. We found that nafadotride at 50 lM for 2 h followed by
ropinirole and rotenone treatment could signiﬁcantly inhibit
ropinirole-mediated anti-apoptosis by more than 65%. How-
ever, sulpiride at 50 lM only blocked 31% of the anti-apopto-
tic eﬀect of ropinirole (Fig. 1C).
In primary cultures with TH and Hoechst double staining,
rotenone treatment at10 nM and 30 nM for 12 h lead to a con-
densed or fragmented nuclei, indicating apoptotic process, in
50–80% TH-ir neurons (Fig. 1A, g–i); while pretreatment with
ropinirole at 10 lM protected TH-ir neurons from fragmented
nuclei, suggesting that ropinirole has anti-apoptotic eﬀect
(Fig. 1A, j–l).
3.2. Ropinirole inhibits P38, JNK and c-Jun phosphorylation
induced by rotenone
SH-SY5Y cells were treated with 10 lM rotenone for 30 min
or 60 min. Expression of p-P38 and p-JNK was signiﬁcantly in-
creased after 10 lM rotenone treatment for 30 min (Fig. 2A
and C, a) or 60 min (Fig. 2B and D, a). Pretreatment
with 50 lM ropinirole 30 min before rotenone addition
(Fig. 2A and C, b; B and D, b) signiﬁcantly decreased the lev-
els of p-P38 and p-JNK. Elevated p-c-Jun was detected
after10 lM rotenone treatment for 2 h (Fig. 2E, a); however,
pretreatment with 50 lM ropinirole for 30 min followed by
rotenone for 2 h could signiﬁcantly decrease the level of p-c-
Jun (Fig. 2E, b).3.3. Ropinirole activates p-ERK1/2
A signiﬁcant increase of p-ERK1/2 in SH-SY5Y cells was
detected after ropinirole treatment at 10–100 lM for 12 h
(Fig. 3A). In addition, time-dependent change in p-ERK1/2
was observed after 50 lM ropinirole treatment for 0.5–12 h
(Fig. 3B). Rotenone exposure at 10 lM for 30 min did not
cause the change in p-ERK1/2 or the ropinirole-mediated
p-ERK1/2 elevation (Fig. 3C).
3.4. Ropinirole reduces cleaves of pro-apoptotic proteins caspase
9, caspase 3 and PARP
SH-SY5Y cells were treated with 10 lM rotenone for 12 h or
pretreated with 50 lM ropinirole for 2 h. Levels of cleaved
caspase 9, cleaved caspase 3 and cleaved PARP were markedly
elevated after 10 lM rotenone treatment for 12 h. Ropinirole
pretreatment could signiﬁcantly suppress the cleavage of
caspase 9, caspase 3 and PARP (Fig. 4A–C).
3.5. Ropinirole elevates anti-apoptotic proteins p-Akt and bcl-2
Treatment with ropinirole upregulated p-Akt and Bcl-2 in a
dose- and time-dependent manner (Fig. 5A and B). The induc-
tion of these proteins was detected when the cells were exposed
to 50 lM ropinirole for 0.5–12 h or exposed to 10–100 lM
ropinirole for 12 h. The levels of p-Akt and Bcl-2 were de-
creased after treatment of 10 lM rotenone for 12 h, ropinirole
pretreatment for 2 h or alone for 12 h at 50 lM could elevate
the expression of p-Akt and Bcl-2 (Fig. 5C).
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Our Study showed that ropinirole has neuroprotective eﬀect
against rotenone-induced apoptosis in both SH-SY5Y cells
and primary VM cultures. We then further investigated the
underlying neuroprotection mechanisms. We found that expo-
sure to rotenone signiﬁcantly activated p-JNK, p-P38 and
p-c-Jun in SH-SY5Y cells. Activation of JNK and P38 is
responsible for the inhibition of the anti-apoptotic protein
Bcl-2, and the induction of phosphorylation of c-Jun, a nuclear
transcription factor and a known target of JNK, which further
promotes the release of cytochrome c from the mitochondria
to the cytoplasm and leads to caspase-9 activation [9–11,14].
Pretreatment with ropinirole inhibits p-JNK, p-P38 and p-c-
Jun expression, indicating that ropinirole may act at early
stage of apoptosis. The ERK1/2 pathway may inhibit the
phosphorylation of Bad, a pro-apoptotic protein belongs to
Bcl-2 family. ERK1/2 phosphorylation can be upregulated
by neurotrophic factors GDNF and BDNF, both of which
were found to increase in the primary mesencephalic cultures
after treatment with ropinirole and pramipexole [22,23]. It is
speculated that ropinirole may induce ERK1/2 phosphoryla-
tion through these two trophic factors. Cleaved caspase 9,
caspase 3 and PARP represent the downstream signals of
apoptosis. Rotenone promoted the cleavage of caspase 9,
caspase 3 and PARP, which could be inhibited by the pretreat-
ment with ropinirole. These results highlight the anti-apoptotic
eﬀect of ropinirole. The most eﬀective doses of anti-apoptotic
eﬀect of ropinirole in our study were between 10 and 100 lM
in SH-SY5Y cells. This result is consistent with the studies of
Joyce et al. showing that the most signiﬁcant neuroprotective
eﬀect of ropinirole occurs from 1 lM to 100 lM in the same
cell line we used [24,25].
Akt and Bcl-2 plays a critical role in controlling the balance
between survival and apoptosis [26–29]. Ropinirole treatment
can enhance the expression of p-Akt and Bcl-2 in both dose-
and time- dependent manner, and can reverse the rotenone-in-
duced downregulation of these two antiapoptotic proteins.
The anti-apoptotic eﬀect of ropinirole can be suppressed by
D2 and D3 receptor antagonists sulpiride and nafadotride.
Nafadotride exhibited greater eﬀect in blocking ropinirole-
mediated anti-apoptosis, suggesting that D3 receptor may play
a signiﬁcant role.
It is clear in the present study that ropinirole has potent anti-
apoptotic eﬀects through its inhibition on: (1) phosphorylation
of JNK, P38, p-c-Jun, and (2) cleaves of caspase 9, caspase 3
and PARP; and (3) stimulation on the phosphorylation of
ERK1/2 and expression of p-Akt and bcl-2. These results pro-
vide further molecular evidence that D2/D3 agonist ropinirole
oﬀers potent neuroprotection, which may warrant further clin-
ical study in PD to determine if the drug can slow down the
disease progression.
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